Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis.
Identifieur interne : 003480 ( PubMed/Curation ); précédent : 003479; suivant : 003481Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis.
Auteurs : Olivier Bruyère [Royaume-Uni] ; Jean-Yves Reginster [Royaume-Uni] ; Nicholas Bellamy [Royaume-Uni] ; Roland Chapurlat [Royaume-Uni] ; Pascal Richette [Royaume-Uni] ; Cyrus Cooper [Royaume-Uni]Source :
- Rheumatology (Oxford, England) [ 1462-0332 ] ; 2014.
Descripteurs français
- KwdFr :
- MESH :
- traitement médicamenteux : Gonarthrose.
- usage thérapeutique : Agents de maintien de la densité osseuse, Thiophènes.
- Adulte d'âge moyen, Femelle, Humains, Mâle, Méthode en double aveugle, Résultat thérapeutique, Sujet âgé.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Bone Density Conservation Agents, Thiophenes.
- drug therapy : Osteoarthritis, Knee.
- Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Treatment Outcome.
Abstract
The aim of this study was to assess the efficacy of strontium ranelate in improving symptoms in knee OA.
DOI: 10.1093/rheumatology/keu018
PubMed: 24667161
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003593
Links to Exploration step
pubmed:24667161Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis.</title><author><name sortKey="Bruyere, Olivier" sort="Bruyere, Olivier" uniqKey="Bruyere O" first="Olivier" last="Bruyère">Olivier Bruyère</name><affiliation wicri:level="1"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford, UK. olivier.bruyere@ulg.ac.be.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford</wicri:regionArea></affiliation></author><author><name sortKey="Reginster, Jean Yves" sort="Reginster, Jean Yves" uniqKey="Reginster J" first="Jean-Yves" last="Reginster">Jean-Yves Reginster</name><affiliation wicri:level="1"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford</wicri:regionArea></affiliation></author><author><name sortKey="Bellamy, Nicholas" sort="Bellamy, Nicholas" uniqKey="Bellamy N" first="Nicholas" last="Bellamy">Nicholas Bellamy</name><affiliation wicri:level="1"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford</wicri:regionArea></affiliation></author><author><name sortKey="Chapurlat, Roland" sort="Chapurlat, Roland" uniqKey="Chapurlat R" first="Roland" last="Chapurlat">Roland Chapurlat</name><affiliation wicri:level="1"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford</wicri:regionArea></affiliation></author><author><name sortKey="Richette, Pascal" sort="Richette, Pascal" uniqKey="Richette P" first="Pascal" last="Richette">Pascal Richette</name><affiliation wicri:level="1"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford</wicri:regionArea></affiliation></author><author><name sortKey="Cooper, Cyrus" sort="Cooper, Cyrus" uniqKey="Cooper C" first="Cyrus" last="Cooper">Cyrus Cooper</name><affiliation wicri:level="1"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24667161</idno><idno type="pmid">24667161</idno><idno type="doi">10.1093/rheumatology/keu018</idno><idno type="wicri:Area/PubMed/Corpus">003593</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003593</idno><idno type="wicri:Area/PubMed/Curation">003480</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003480</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis.</title><author><name sortKey="Bruyere, Olivier" sort="Bruyere, Olivier" uniqKey="Bruyere O" first="Olivier" last="Bruyère">Olivier Bruyère</name><affiliation wicri:level="1"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford, UK. olivier.bruyere@ulg.ac.be.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford</wicri:regionArea></affiliation></author><author><name sortKey="Reginster, Jean Yves" sort="Reginster, Jean Yves" uniqKey="Reginster J" first="Jean-Yves" last="Reginster">Jean-Yves Reginster</name><affiliation wicri:level="1"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford</wicri:regionArea></affiliation></author><author><name sortKey="Bellamy, Nicholas" sort="Bellamy, Nicholas" uniqKey="Bellamy N" first="Nicholas" last="Bellamy">Nicholas Bellamy</name><affiliation wicri:level="1"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford</wicri:regionArea></affiliation></author><author><name sortKey="Chapurlat, Roland" sort="Chapurlat, Roland" uniqKey="Chapurlat R" first="Roland" last="Chapurlat">Roland Chapurlat</name><affiliation wicri:level="1"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford</wicri:regionArea></affiliation></author><author><name sortKey="Richette, Pascal" sort="Richette, Pascal" uniqKey="Richette P" first="Pascal" last="Richette">Pascal Richette</name><affiliation wicri:level="1"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford</wicri:regionArea></affiliation></author><author><name sortKey="Cooper, Cyrus" sort="Cooper, Cyrus" uniqKey="Cooper C" first="Cyrus" last="Cooper">Cyrus Cooper</name><affiliation wicri:level="1"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford</wicri:regionArea></affiliation></author></analytic><series><title level="j">Rheumatology (Oxford, England)</title><idno type="eISSN">1462-0332</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Bone Density Conservation Agents (therapeutic use)</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Osteoarthritis, Knee (drug therapy)</term><term>Thiophenes (therapeutic use)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Agents de maintien de la densité osseuse (usage thérapeutique)</term><term>Femelle</term><term>Gonarthrose (traitement médicamenteux)</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Thiophènes (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bone Density Conservation Agents</term><term>Thiophenes</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Osteoarthritis, Knee</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Gonarthrose</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents de maintien de la densité osseuse</term><term>Thiophènes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Résultat thérapeutique</term><term>Sujet âgé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this study was to assess the efficacy of strontium ranelate in improving symptoms in knee OA.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24667161</PMID><DateCreated><Year>2014</Year><Month>07</Month><Day>19</Day></DateCreated><DateCompleted><Year>2014</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1462-0332</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>8</Issue><PubDate><Year>2014</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Rheumatology (Oxford, England)</Title><ISOAbbreviation>Rheumatology (Oxford)</ISOAbbreviation></Journal><ArticleTitle>Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis.</ArticleTitle><Pagination><MedlinePgn>1457-64</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/rheumatology/keu018</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to assess the efficacy of strontium ranelate in improving symptoms in knee OA.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Symptoms were assessed over 3 years in patients with primary knee OA receiving strontium ranelate 2 g/day (n = 454), 1 g/day (n = 445) or placebo (n = 472) in the Strontium Ranelate Efficacy in Knee Osteoarthritis Trial. Clinical response was evaluated using WOMAC subscores, minimal perceptible clinical improvement (MPCI), minimal clinically important improvement (MCII) and a modified OMERACT-Osteoarthritis Research Society International (OARSI) responder definition. Patients who withdrew prematurely from the study were considered non-responders.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There was no significant effect on symptoms for strontium ranelate 1 g/day. At the dosage of 2 g/day, strontium ranelate was associated with greater response than placebo in terms of ≥20% improvement in WOMAC pain from baseline to the last visit (58% vs 47%, P = 0.002) and ≥50% improvement in WOMAC pain (42% vs 36%, P = 0.083). Significant differences were found in MPCI response for WOMAC pain (52% vs 40%, P < 0.001), stiffness (47% vs 39%, P = 0.009) and physical function (46% vs 37%, P = 0.009) and in MCII response for WOMAC physical function (46% vs 37%, P = 0.013). There were also more OMERACT-OARSI-like responders with strontium ranelate (44% vs 35%, P = 0.004). The treatment-placebo difference in MPCI response for WOMAC pain was significant after 6 months (P = 0.024), while that in MPCI and MCII response for WOMAC physical function reached significance after 12 months (P = 0.027 and P = 0.019, respectively).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Treatment with strontium ranelate 2 g/day over 3 years is associated with a clinically meaningful improvement in pain from 6 months as well as physical function and stiffness as assessed by the number of responders above thresholds of clinical relevance.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Current Controlled Trials. http://www.controlled-trials.com/ (ISRCTN41323372).</AbstractText><CopyrightInformation>© The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bruyère</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford, UK. olivier.bruyere@ulg.ac.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reginster</LastName><ForeName>Jean-Yves</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellamy</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chapurlat</LastName><ForeName>Roland</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richette</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Cyrus</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium, School of Medicine, University of Queensland, Herston, Queensland, Australia, INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France, Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris Cedex, France and MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, and NIHR Biomedical Research Unit, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>SEKOIA investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ISRCTN</DataBankName><AccessionNumberList><AccessionNumber>ISRCTN41323372</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>MC_UP_A620_1014</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_12011/1</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rheumatology (Oxford)</MedlineTA><NlmUniqueID>100883501</NlmUniqueID><ISSNLinking>1462-0324</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050071">Bone Density Conservation Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013876">Thiophenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>04NQ160FRU</RegistryNumber><NameOfSubstance UI="C081587">strontium ranelate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050071" MajorTopicYN="N">Bone Density Conservation Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020370" MajorTopicYN="N">Osteoarthritis, Knee</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013876" MajorTopicYN="N">Thiophenes</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SEKOIA</Keyword><Keyword MajorTopicYN="N">osteoarthritis</Keyword><Keyword MajorTopicYN="N">pain</Keyword><Keyword MajorTopicYN="N">responder criteria</Keyword><Keyword MajorTopicYN="N">strontium ranelate</Keyword><Keyword MajorTopicYN="N">symptoms</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24667161</ArticleId><ArticleId IdType="pii">keu018</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/keu018</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003480 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003480 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:24667161
|texte= Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:24667161" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |